Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Upcoming Events

The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care 

Join us to learn about advances in the treatment of MASH, including the basis for and benefits of pharmacologic strategies for modifying body weight. 

Live Meeting
1.50 available credits
Information
November 16, 2024
07:30 PM - 09:30 PM PT
Marriott Marquis San Diego Marina
333 W Harbor Dr, San Diego, CA 92101, Grand Ballroom 1, 2, 5 (Lobby Level), United States
ReachMD Healthcare Image
Details
Presenters
Comments

  • Overview

    MASLD/MASH is a serious, chronic, progressive disease and will soon be the most common indication for liver transplantation and major driver of the development of liver cancer. Until recently there was no liver-directed therapy for MASH and the metabolic benefits of pharmacologic modification of body weight in the management of MASLD/MASH were underappreciated. This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment monitoring for disease progression, and long-term medical management, including the role of incretin agonists. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.   

    Host:  
    Naim Alkhouri, MD, FAASLD, DABOM   
    Chief Medical Officer   
    Director of the Steatotic Liver Program   
    Chief of Transplant Hepatology   
    Arizona Liver Health   
    Phoenix, AZ  

     Dr. Naim Alkhouri has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:   
    Research: 89Bio, Akero, Arbutus, AstraZeneca, Better Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Corcept, CymaBay, DSM, Galectin, Genentech, Genfit, Gilead, Healio, Hepagene, Intercept, Inventiva, Ionis, Ipsen, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, and Zydus.    
    Consulting Fees: 89Bio, AbbVie, Boehringer Ingelheim, Echosens, Fibronostics, Gilead, Intercept, Ipsen, Madrigal, NorthSea, Novo Nordisk, Perspectum, Pfizer, and Zydus.   

    Faculty:  
    Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP  
    Director, Campbell University Health Center  
    Chair and Associate Professor of Family Medicine  
    Buies Creek, NC  

    Dr. Nicholas Pennings has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Consulting Fees: Abbott 
    Other: Medifast  

    Amreen M. Dinani, MD, FRCPC  
    Associate Professor of Medicine  
    Gastroenterology   
    Duke University School of Medicine  
    Durham, NC  

    Dr. Amreen Dinani has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Consulting Fees: Madrigal Pharmaceuticals, Novo Nordisk 
    Research: GSK, Hanmi, Inventiva, Liver Cirrhosis Network, Madrigal Pharmaceuticals, NIDDK 

    Reviewers/Content Planners/Authors:  

    • Cindy Davidson has nothing to disclose.        
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose. 
    • Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.    
    • Rosanne Strauss, PharmD, has nothing to disclose.    

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Summarize the pathophysiologic rationale for using obesity pharmacotherapy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH)  
    • Apply recommendations for the treatment of patients with MASLD/MASH with GLP-1 RAs  
    • Devise a multidisciplinary plan to manage obesity in patients with MASLD/MASH  
    • Interpret data from clinical trials of emerging liver-directed therapies for MASLD/MASH  
    • Interpret data from clinical trials of emerging anti-obesity therapies for MASLD/MASH 

  • Target Audience

    This activity has been designed to meet the educational needs of hepatologists and advanced practice providers who work in hepatology practices, as well as gastroenterologists and all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with MASLD/MASH.  

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Obesity Medicine Association. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

     Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.  

     Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours. 
     
    The Universal Activity Number for this program is JA0006235-0000-24-092-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).   

  • Provider(s)/Educational Partner(s)

     
    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.  

  • Commercial Support

    This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc. 

  • Disclaimer

    Presented for attendees of The Liver Meeting® 2024. This event/function is provided by Medtelligence and supported by Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc. This is not an official event/function of the American Association for the Study of Liver Diseases.

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Details
Presenters
Comments
Recommended

  • Overview

    MASLD/MASH is a serious, chronic, progressive disease and will soon be the most common indication for liver transplantation and major driver of the development of liver cancer. Until recently there was no liver-directed therapy for MASH and the metabolic benefits of pharmacologic modification of body weight in the management of MASLD/MASH were underappreciated. This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment monitoring for disease progression, and long-term medical management, including the role of incretin agonists. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.   

    Host:  
    Naim Alkhouri, MD, FAASLD, DABOM   
    Chief Medical Officer   
    Director of the Steatotic Liver Program   
    Chief of Transplant Hepatology   
    Arizona Liver Health   
    Phoenix, AZ  

     Dr. Naim Alkhouri has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:   
    Research: 89Bio, Akero, Arbutus, AstraZeneca, Better Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Corcept, CymaBay, DSM, Galectin, Genentech, Genfit, Gilead, Healio, Hepagene, Intercept, Inventiva, Ionis, Ipsen, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, and Zydus.    
    Consulting Fees: 89Bio, AbbVie, Boehringer Ingelheim, Echosens, Fibronostics, Gilead, Intercept, Ipsen, Madrigal, NorthSea, Novo Nordisk, Perspectum, Pfizer, and Zydus.   

    Faculty:  
    Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP  
    Director, Campbell University Health Center  
    Chair and Associate Professor of Family Medicine  
    Buies Creek, NC  

    Dr. Nicholas Pennings has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Consulting Fees: Abbott 
    Other: Medifast  

    Amreen M. Dinani, MD, FRCPC  
    Associate Professor of Medicine  
    Gastroenterology   
    Duke University School of Medicine  
    Durham, NC  

    Dr. Amreen Dinani has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Consulting Fees: Madrigal Pharmaceuticals, Novo Nordisk 
    Research: GSK, Hanmi, Inventiva, Liver Cirrhosis Network, Madrigal Pharmaceuticals, NIDDK 

    Reviewers/Content Planners/Authors:  

    • Cindy Davidson has nothing to disclose.        
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose. 
    • Susan Smith, MN, PhD, has ownership interest in Hepion Pharmaceuticals.    
    • Rosanne Strauss, PharmD, has nothing to disclose.    

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Summarize the pathophysiologic rationale for using obesity pharmacotherapy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH)  
    • Apply recommendations for the treatment of patients with MASLD/MASH with GLP-1 RAs  
    • Devise a multidisciplinary plan to manage obesity in patients with MASLD/MASH  
    • Interpret data from clinical trials of emerging liver-directed therapies for MASLD/MASH  
    • Interpret data from clinical trials of emerging anti-obesity therapies for MASLD/MASH 

  • Target Audience

    This activity has been designed to meet the educational needs of hepatologists and advanced practice providers who work in hepatology practices, as well as gastroenterologists and all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with MASLD/MASH.  

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Obesity Medicine Association. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

     Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.  

     Global Learning Collaborative (GLC) designates this activity for 1.5 contact hours/0.15 CEUs of pharmacy contact hours. 
     
    The Universal Activity Number for this program is JA0006235-0000-24-092-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).   

  • Provider(s)/Educational Partner(s)

     
    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.  

  • Commercial Support

    This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc. 

  • Disclaimer

    Presented for attendees of The Liver Meeting® 2024. This event/function is provided by Medtelligence and supported by Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc. This is not an official event/function of the American Association for the Study of Liver Diseases.

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Recommended

Schedule12 Dec 2024
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended